Topics
Glioblastoma | Treatment | Immunotherapy | Bispecific antibody armed T cells
Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > Bispecific antibody armed T cells
Fadul CE, Thakur A, Kim J, Kassay-McAllister J, Schalk D, Lopes
MB, Donahue J, Purow B, Dillon P, Le T, Schiff D, Liu Q, Lum
LG.
Phase I study targeting newly
diagnosed grade 4 astrocytoma with bispecific antibody armed T
cells (EGFR BATs) in combination with radiation and
temozolomide.
J
Neurooncol. 2024 Jan 23;166(2):321-330. doi:
10.1007/s11060-024-04564-y. PMID:
38263486. Interventional
study. ˍ
Whittle JR, Vieito M, Rohrberg K, Rodriguez-Ruiz ME, Castanon E,
Mellinghoff IK, Van Linde M, Cloughesy T, Reardon DA, Chong RA,
Rosenthal M, Wick A, Waldhauer I, Henkel N, Romagnoli B, Wolowski
V, Dey S, Heil F, Heichinger C, Flinn N, Gou JP, Smith L, Prince
F, Derks M, Roller A, Schiff C, Schneider M, Mason W.
First-in-human study of an EGFRvIII x
CD3 T cell bispecific antibody in the treatment of newly diagnosed
glioblastoma.
Neurooncol
Adv. 2025 Jul 18;7(1):vdaf160. doi:
10.1093/noajnl/vdaf160. PMID:
40842640. Interventional
study. ˍ
ClinicalTrial.gov
ID: NCT05187624.